BOEHRINGER-INGELHEIM
8.3.2016 09:18:41 CET | Business Wire | Press release
Boehringer Ingelheim today announced the presentation of new post-hoc analyses that show the addition of SPIRIVA® (tiotropium) Respimat® to other asthma maintenance therapies helps improve lung function and asthma symptom control, while reducing asthma exacerbations (also known as flare-ups), independent of a patient’s subtype of allergic asthma.1,2,3 These data were presented at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Los Angeles.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160308005699/en/
These analyses evaluated the safety and efficacy of adding SPIRIVA® Respimat® to other maintenance therapies compared to placebo across the broad range of asthma patients studied, regardless of the allergic (Immunoglobulin E or IgE) and inflammatory (eosinophilic) levels.
The addition of SPIRIVA® Respimat® significantly improved lung function.*3 Adding SPIRIVA® Respimat® also was shown to improve asthma symptom control, as measured by the seven question Asthma Control Questionnaire (ACQ-7)2 and reduce the risk of asthma worsening and exacerbations.1
“The data confirm that adding SPIRIVA® Respimat® is a well-tolerated and effective treatment option for asthma patients independent of allergic subtype,” said Mark Vandewalker, MD, director, Clinical Research of the Ozarks, Columbia, Missouri. “For people with allergic asthma who are still experiencing symptoms, adding SPIRIVA® Respimat® may help open airways to improve breathing.”
People living with allergic asthma – the most common form of the condition – experience inflammation and a tightening of the airways due to exposure to common allergens. These patients may need other inhaled options that complement their existing therapy.
SPIRIVA® Respimat® is the first new class of inhaled medicine approved in over 10 years for asthma.5 It complements a patient’s other maintenance therapies (usually ICS/LABA) to reduce asthma symptoms and the risk of asthma flare-ups. SPIRIVA® Respimat® in asthma is delivered by Respimat® , the inhaler which actively† delivers a unique mist,6 meaning the patient just needs to take a deep breath in7 for the medication to go deep into the lungs.8,9,10
“Boehringer Ingelheim is committed to pursuing scientific research to help address unmet needs and improve patient care for people living with asthma,” said William Mezzanotte, Head of Respiratory Medicine, Boehringer Ingelheim. “These data further demonstrate the benefits of SPIRIVA® Respimat® for the broad range of asthma patients studied who continued to experience symptoms despite taking other maintenance therapies, regardless of allergy subtype.”
The post-hoc analyses are based on data from the two PrimoTinA-asthma® and two MezzoTinA-asthma® trials which are part of the UniTinA-asthma® large-scale clinical trial programme:
- The PrimoTinA-asthma® trials investigated SPIRIVA® Respimat® as an add-on therapy for adults with asthma who continued to have symptoms despite taking at least ICS/LABA therapy.
- The MezzoTinA-asthma® trials investigated SPIRIVA® Respimat® as an add-on therapy for adults with asthma who continued to have symptoms despite taking at least moderate-dose ICS therapy.
The safety and tolerability of SPIRIVA® Respimat® in each trial and treatment group were comparable with those of placebo in the overall patient population.4,11
For more information please visit www.boehringer-ingelheim-congress.com and www.respimat.com
For more information on SPIRIVA® RESPIMAT® and asthma, please visit Boehringer Ingelheim News Centre .
For references and notes to editors please visit http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2016/08_march_2016_asthma.html
* As measured by peak forced expiratory volume (volume of air that can be forced out after taking a deep breath) in one second (FEV1) and trough FEV1
† Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation
View source version on businesswire.com: http://www.businesswire.com/news/home/20160308005699/en/
Contact:
Boehringer Ingelheim
Katharina Opitz
Phone: +49 6132 - 77 2012
Fax:
+49 6132 - 77 6601
Email: press@boehringer-ingelheim.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Modon Partners With Montage Hotels & Resorts to Bring Ultra-Luxury Hospitality Brand to Egypt’s Ras El Hekma17.5.2026 13:53:00 CEST | Press release
Montage Ras El Hekma introduces the first branded residences for purchase at the Mediterranean destination, alongside the region’s first Montage resort Abu Dhabi-based Modon Holding and Montage Hotels & Resorts have announced Montage Ras El Hekma, which will introduce the first branded residences for purchase at Ras El Hekma on Egypt’s Mediterranean coast. This is the first Montage resort in Egypt – supporting the emerging city’s growth as a global hub for leisure, business and tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517167234/en/ Modon partners with Montage Hotels & Resorts to bring ultra-luxury hospitality brand to Egypt’s Ras El Hekma (Photo: AETOSWire) Montage Ras El Hekma will feature 200 guestrooms and suites, in addition to 96 Montage Residences, and will offer a curated mix of wellness and leisure amenities, including beachfront swimmable lagoons, a Spa Montage with 13 treatment rooms, and six dini
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center17.5.2026 08:00:00 CEST | Press release
Compact, vault-integrated platform selected through a competitive European tender will bring proton therapy to patients across Southern Italy. Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been selected to deliver the MEVION S250-FIT Proton Therapy System™ to Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples. The award, made following a competitive European tender, will establish the first proton therapy center in Southern Italy, significantly expanding access to advanced radiation therapy for patients across the region and reducing the need for patients to travel long distances to northern Italy for care. Until now, proton therapy in Italy has only been available at centers located in Northern Italy, requiring patients from Southern Italy to travel significant distances for care. The Pascale project supports a broader strategy to establish Naples as a leading oncology hub and to improve healthcare equity across Italy. “T
TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone16.5.2026 10:43:00 CEST | Press release
TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260516556464/en/ Photograph of the MLX200 chip with a five-cent coin for size reference The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems. As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation dir
STARTEEPO Invest Announces 5% Stake in Xerox Holdings Corporation15.5.2026 18:15:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has acquired a significant ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515594020/en/ As of the date of this release, STARTEEPO and its affiliates beneficially owns 6.6 million shares of Xerox (excluding options), representing approximately 5.05% of the Company’s outstanding common stock. STARTEEPO has filed a Schedule 13D with the U.S. Securities and Exchange Commission (the “SEC”) providing additional details regarding its investment. Investment Perspective STARTEEPO believes that Xerox represents an interesting investment opportunity supported by a combination of balance sheet initiatives, ongoing operational improvements, and its position within a changing and consolidating industry. In STARTEEPO’s view, the Company
NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 16:00:00 CEST | Press release
Accelerates AI‑driven transformation through expanded agentic AI and data engineering capabilities that underpin NTT DATA’s AI strategy Adds 1,000 Azure engineers and AI specialists to scale cloud and AI delivery capabilities Advances NTT DATA’s North America leadership position, scaling industry aligned AI led innovation across its cloud services and Microsoft Business Unit Builds on NTT DATA’s position as the fastest-growing Microsoft GSI partner, accelerating co-innovation in enterprise AI NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire,an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale. The acquisition further advances NTT DATA’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom